Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.38 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31406695 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL5251610 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL9269091 | 0.87 | GRM5 (0.36) | USP2SMN1; SMN2ALDH1A1 | |
| SCHEMBL27743952 | 0.86 | USP2 (0.41) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL29207289 | 0.86 | USP2 (0.41) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL18618412 | 0.85 | ADORA1 (0.42) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL29450194 | 0.85 | ADORA1 (0.42) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL27143468 | 0.85 | EPHX2 (0.39) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL31406665 | 0.83 | ESR2 (0.36) | USP2SMN1; SMN2ESR2NR1H2DDB1 | |
| SCHEMBL31491069 | 0.83 | ESR2 (0.36) | USP2SMN1; SMN2ESR2NR1H2DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116882-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12448400-B2 | KRAS G12D modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| EP-4596551-A1 | COMPOUNDS WITH ANTI-KRAS MUTANT TUMOR ACTIVITY | Trasveda Ltd. (KY) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025108443-A2 | HETEROCYCLIC COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BEIGENE SWITZERLAND GMBH (CH) | 2025-05-30 | — | — | WO | disclosed |
| US-20250136621-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-05-01 | — | — | US | disclosed |
| US-20250109147-A1 | KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-04-03 | — | — | US | disclosed |
| WO-2025059040-A1 | MUTANT KRAS MODULATORS AND USES THEREOF | NEWAVE PHARMACEUTICAL INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025054530-A1 | PYRIMIDINE-CONTAINING POLYCYCLIC DERIVATIVES AS KRAS G12D MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025051242-A1 | RAS INHIBITOR | 泰励生物科技（上海）有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119591588-A | RAS inhibitors | 泰励生物科技（上海）有限公司 | 2025-03-11 | — | — | CN | disclosed |
| WO-2003045942-A2 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | CARPINO PHILIP ALBERT (US) | 2003-05-29 | — | — | US | disclosed |
| US-6482825-B2 | HEXAHYDRO-PYRAZOLO-(4,3-C)PYRIDINE DERIVATIVES USEFUL FOR INCREASING THE ENDOGENOUS PRODUCTION OR RELEASE OF GROWTH HORMONE IN A HUMAN OR OTHER ANIMAL, THUS TREAT OR PREVENT OSTEOPOROSIS | PFIZER INC. | 2002-11-19 | — | — | US | disclosed |
| US-6448263-B1 | SYNTHESIS ROUTES FOR SUCH AS 2-AMINO-N-(2-(3A-(R)-BENZYL-2-METHYL-3-OXO-2,3,3A,4,6,7-HEXAHYDRO-PYRAZOLO -(4,3-C) PYRIDIN-5-YL)-1-(R)-BENZYLOXYMETHYL-2-OXO-ETHYL)-ISOBUTYRAMIDE L-TARTARIC ACID SALT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| US-20020049196-A1 | Growth-hormone secretagogues | RAQUALIA PHARMA INC. (JP) | 2002-04-25 | — | — | US | disclosed |
| US-6313140-B1 | ADMINISTERING TO A HUMAN OR OTHER ANIMAL PYRAZOLOPYRIMIDINE DERIVATIVE FOR PROPHYLAXIS OR THERAPY OF DISEASE OR CONDITION WHICH MAY BE TREATED OR PREVENTED BY GROWTH HORMONE | PFIZER INC. | 2001-11-06 | — | — | US | disclosed |
| US-6306875-B1 | ADMINISTERING GROWTH HORMONES DIPEPTIDE COMPOUNDS WHICH ARE GROWTH HORMONE SECRETAGOGUES AND ARE USEFUL FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS. | PFIZER INC. | 2001-10-23 | — | — | US | disclosed |
| US-6278000-B1 | INCREASE LEVEL OF ENDOGENOUS GROWTH HORMONE; USEFUL IN THERAPY AND PROPHYLAXIS OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING AND OBESITY, ACCELERATING BONE FRACTURE REPAIR | PFIZER INC. | 2001-08-21 | — | — | US | disclosed |
| US-6110932-A | INCREASE THE LEVEL OF ENDOGENOUS GROWTH HORMONE FOR THE TREATMENT AND PREVENTION OF OSTEOPOROSIS, CONGESTIVE HEART FAILURE, FRAILTY ASSOCIATED WITH AGING, OBESITY; ACCELERATING BONE FRACTURE REPAIR, ACCELERATING WOUND HEALING | PFIZER INC. (US) | 2000-08-29 | — | — | US | disclosed |
| US-6107306-A | OSTEOPOROSIS | PFIZER INC. (US) | 2000-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100561-A1 | Administering 2-amino-N-(1-(3a-benzyl-2-methyl-3-oxo-2,3,3a, 4,6,7-hexahydro-pyrazolo(4,3-c)pyridine-5-carbonyl)-4-phenyl-butyl) -isobutyramide for treating congestive heart failure, obesity | GIPR, GHSR, GPR119 | USP2 1366/4885SMN1; SMN2 1144/4885ESR2 644/4885 |
| US-20260116882-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | USP2 1804/4885SMN1; SMN2 3109/4885ESR2 3027/4885 |
| US-12448400-B2 | KRAS G12D modulating compounds | KRAS, NRAS, HRAS | USP2 1176/4885SMN1; SMN2 3013/4885ESR2 2324/4885 |
| US-20250136621-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | USP2 1176/4885SMN1; SMN2 3013/4885ESR2 2324/4885 |
| US-20250109147-A1 | KRAS G12D MODULATING COMPOUNDS | KRAS, NRAS, HRAS | USP2 1176/4885SMN1; SMN2 3013/4885ESR2 2324/4885 |
| US-20020049196-A1 | Growth-hormone secretagogues | GHSR, GHRHR, IGFBP6 | USP2 3413/4885SMN1; SMN2 1659/4885ESR2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.